Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
F182112 in Relapsed or Refractory Multiple Myeloma
NCT04984434Phase 1Unknown
- Sponsor
- Shandong New Time Pharmaceutical
- Start
- Jul 2021
- Primary completion
- Jul 2023
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of F182112 in multiple myeloma (MM), sponsored by Shandong New Time Pharmaceutical. Primary endpoints: Dose-Limiting Toxicities at 28 days, Maximum Tolerated Dose at 12 months and 1 more. Status: unknown.
02
Drugs
F182112
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04984434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04984434.